Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) typically progress silently; in fact, often people will show no infections. For example, 50% of men infected with CT – and 80% of women – will not exhibit any signs of the infection. Left untreated, these common sexually transmitted infections can cause infertility and other serious health complications. Early detection is critically important – and the driving force behind Hologic’s development of the Aptima Combo 2 test. This simple, cost-effective assay screens for both chlamydia and gonorrhea, providing two results from a single swab or urine sample that can be taken right in the clinic or office. By using this highly specific and sensitive test, laboratories can improve workflow and throughput, while clinicians can identify and treat individuals with underlying infections – and reduce the serious effects and costly consequences if left untreated – in sexually active individuals.
The Aptima Combo 2 test has been shown to be clinically more sensitive to culture and non-amplified tests for the screening of both chlamydia and gonorrhea from just one sample. Because of its excellent sensitivity, this target amplification nucleic acid probe test gives healthcare providers the flexibility to use multiple specimen types.
Sample types include:
- Vaginal swab - clinician or patient-collected.
- Unisex swab - female endocervical/male urethral.
- Urine - female or male.
- The ThinPrep Pap test vial - add-on to the Pap test.
It can be ordered as a standalone test or added to the Pap test - right in your clinic or office.
In addition to the Aptima Combo 2 test for CT/NG, Hologic also offers separate Aptima screening tests for chlamydia or gonorrhea, should only one condition be suspected.
Chlamydia and gonorrhea are common and curable STIs caused by the bacteria Chlamydia trachomatis and Neisseria gonorrheae. The Centers for Disease Control and Prevention (CDC) estimates that nearly 3.7 million new chlamydia and gonorrhea infections occur each year, more than half of which affect young people aged 15-24.1-3 While the infections are quite common, 3 out of 4 patients infected will show no symptoms.1,2 And if left untreated, these infections can lead to such serious health complications as pelvic inflammatory disease (PID), infertility, chronic pelvic pain and ectopic pregnancy.
The CDC recommends the following screening guidelines for chlamydia and gonorrhea:3
- Annual testing for chlamydia in sexually active women aged 25 and younger.
- Annual testing for chlamydia and gonorrhea in women who have had a new sexual partner in the last year.
- All pregnant women should be tested for chlamydia.
- Those with additional risk factors should also be tested for gonorrhea.
- Re-testing in 3 months for patients who have tested positive and undergone treatment for either chlamydia or gonorrhea.
- Satterwhite CL, et al. Sex Transm Dis. 2013; CDC Fact Sheet. 2013.
- Thomas A. Farley, M.D., M.P.H., Preventive Medicine, 2003.
- Centers for Disease Control and Prevention. CDC Fact Sheet: Incidence, Prevalence, and Cost of Sexually Transmitted Infections in the United States. February 2013. Available at http://www.cdc.gov/std/stats/STI-Estimates-Fact-Sheet-Feb-2013.pdf. Retrieved June 24, 2013.